2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1815 Docirbrutinib, a non-covalent pan-mutant Bruton’s tyrosine kinase (BTK) inhibitor, in patients with previously treated mantle cell lymphoma, Waldenström macroglobulinemia, and other B-cell malignancies: Phase 1b study update

Nirav N. Shah, MD, MS, Jonathan S. Goldberg2, John Nemunaitis, MD3, Catherine C. Coombs4, Jacqueline Barrientos, MD5, Danielle Brander, MD6, Andrew Gillis-Smith, MD7, Sunil Babu8, Seung Tae Lee, MD, PhD9, Shuo Ma, MD10, Koji Yoshida, MD, PhD11, Masaaki Sawa, PhD12, Kyoko Miyamoto, MD, PhD13, Akinori Arimura, PhD14, Nitin Jain, MD15, Javier Pinilla-Ibarz, MD PhD16
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Optum Medical Care, Mount Kisco, New York, United States
3 Taylor Cancer Research Center, Maumee, Ohio, United States
4 University of California Irvine Health, Irvine, California, United States
5 Mount Sinai Medical Center, Miami Beach, Florida, United States
6 Duke Cancer Institute, Durham, North Carolina, United States
7 University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
8 American Oncology Partners, Fort Wayne, Indiana, United States
9 University of Maryland Medical Center, Baltimore, Maryland, United States
10 Robert H. Lurie Comprehensive Cancer Center, Northwestern Memorial Hospital, Chicago, Illinois, United States
11 Carna Biosciences, Inc., Kobe, Japan
12 Carna Biosciences, Inc., Kobe, Japan
13 CarnaBio USA, Inc., South San Francisco, California, United States
14 CarnaBio USA, Inc., South San Francisco, California, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 Moffitt Cancer Center, Tampa, Florida, United States

Background:

Docirbrutinib (AS-1763) is a highly selective, pan-mutant non-covalent BTK inhibitor (ncBTKi), which inhibits both wild-type and various c/ncBTKi-resistant mutations including C481x, T474x and L528x with IC50 values of <10 nM and shows strong anti-tumor activity in B-cell lymphoma cell lines harboring resistant BTK mutations including a kinase-dead BTK L528W. Here we present updated efficacy data for docirbrutinib in patients (pts) with mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL), with updated safety data for all pts, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), from the ongoing Phase 1b study of docirbrutinib in B-cell malignancies (NCT05602363).

Methods:

This is a multicenter, open-label, Phase 1b study in pts with CLL/SLL or B-cell non-Hodgkin lymphoma (NHL) who received ≥2 prior therapies, including c/ncBTKis. The study includes dose-escalation and dose-expansion parts. The dose expansion part includes three cohorts: CLL/SLL (Cohort 1) and NHL (Cohort 2) for determination of the recommended Phase 2 dose (RP2D), and pirtobrutinib (ncBTKi)-pretreated CLL/SLL and MCL (Cohort 3) for exploratory efficacy evaluation. Docirbrutinib was administered orally at doses ranging from 100-500 mg twice daily (BID). Safety is presented for all pts enrolled in the study. Efficacy is presented for pts with B-cell NHL including MCL, WM, MZL and FL. Tumor response was assessed by investigators per Lugano for MCL, MZL and FL, and IWWM6 for WM.

Results:

As of 10 July 2026, 25 pts with MCL (n=9), WM (n=4), MZL (n=6), and FL (n=6) were assigned to 4 dose levels: 200 (n=1), 300 (n=11), 400 (n=11), and 500 mg BID (n=2). Median age was 68 years (range, 46-86). Median number of prior lines of therapy was 6 (range, 2-8) for MCL, 5 (range, 2-6) for WM, 4 (range, 2-8) for MZL, and 4 (range, 2-6) for FL. Prior therapies included cBTKi (4/9 [44%] for MCL, 2/4 [50%] for WM, 2/6 [33%] for MZL, and 1/6 [17%] for FL) and ncBTKi (2/9 [22%] for MCL). All 58 pts who received docirbrutinib in the Phase 1b study, including those with CLL/SLL, were evaluated for safety, with a median treatment duration of 8.3 months (range, 0.6-35.3). The most common treatment-emergent adverse events (TEAEs, ≥20%) were diarrhea (28%; no Grade [G] ≥3), nausea (21%; no ≥G3), and upper respiratory tract infection (21%; no ≥G3). No drug-related atrial fibrillation or hypertension was reported. Drug-related ≥G3 adverse events (AEs) were reported in 7 pts (12%): neutrophil count decreased or neutropenia in 3 pts (5%), ALT and/or AST increased in 2 pts (3%), hematuria in 1 pt (2%), hematoma on concomitant anticoagulation and subsequent anemia and hemorrhagic shock in 1 pt (2%), and hypokalemia in 1 pt (2%). Due to drug-related AEs, 3 pts (5%) experienced dose interruption (G3 ALT and/or AST increased in 2 pts and G3 hypolakemia in 1 pt), and 1 pt (2%) discontinued treatment (G4 hematoma).

Among 7 pts with ncBTKi-naïve MCL, including 3 pts previously treated with a cBTKi, the overall response rate (ORR) was 100% (7/7; 4 complete responses and 3 partial responses [PRs]). All pts remain on treatment without disease progression. After a median follow-up of 8.9 months (range, 4.2-27.4), the median progression-free survival (PFS) has not yet been reached, and 2 pts have remained progression-free for >18 months. In Cohort 3, 2 MCL pts with prior ncBTKi were enrolled; 1 pt achieved stable disease (SD), and 1 pt experienced progression disease (PD).

Among 4 pts with WM, including 1 pt previously exposed to a cBTKi and 1 pt previously double-exposed to cBTKi and BCL2i, the ORR (minor response or better) and the major response rate (PR or better) were both 100% (4/4; 4 PRs). 3 of 4 pts remain on treatment, with 3 pts having achieved PFS >12 months.

Among 5 efficacy-evaluable pts with MZL (1 of 6 pts has no post-dosing CT assessment yet), including 2 pts previously exposed to cBTKi, and 6 pts with FL, including 1 pt previously treated with cBTKi, the ORR was 40% (2/5; 2 PRs, 1 SD, and 2 PDs) and 0% (0/6; 3 SDs and 3 PDs), respectively.

Conclusion:

Docirbrutinib demonstrated a favorable safety profile and robust, durable efficacy in pts with relapsed/refractory MCL, MZL, and WM despite prior cBTKi exposure, supporting its potential to address significant unmet medical needs and further clinical development in B-cell malignancies.

Nirav N. Shah, MD, MS: Nurix, Gilead-Kite, BMS-Juno, Miltenyi Biomedicine, Lilly Oncology, Incyte, AbbVie, BeoNE, Kite, AstraZeneca, Genentech, Tundra, Adaptive Biotechnologies - Current holder of stock options in a privately-held company; Tundra Therapeutics - Current holder of stock options in a privately-held company; Nurix, Gilead-Kite, BMS-Juno, Miltenyi Biomedicine, Lilly Oncology, Incyte, AbbVie, BeoNE, Kite, AstraZeneca, Genentech, Tundra, Adaptive Biotechnologies - Honoraria; Nurix, Gilead-Kite, BMS-Juno, Miltenyi Biomedicine, Lilly Oncology, Incyte, AbbVie, BeoNE, Kite, AstraZeneca, Genentech, Tundra, Adaptive Biotechnologies - Research Funding; Miltenyi Biomedicine - Research Funding; Lilly Oncology - Research Funding; Incyte - Consultancy (Includes expert testimony); BMS-Juno - Consultancy (Includes expert testimony); Legend - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Lilly Oncology - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Nurix, Gilead-Kite, BMS-Juno, Miltenyi Biomedicine, Lilly Oncology, Incyte, AbbVie, BeoNE, Kite, AstraZeneca, Genentech, Tundra, Adaptive Biotechnologies - Consultancy (Includes expert testimony); Miltenyi Biomedicine - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony)